QS Investors’s Clearside Biomedical CLSD Stock Holding History

QS Investors’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$545K	Hold	7,460	–	–	0.01%	703
2021 Q1	$277K	Buy	+7,460	New	+$375K	﹤0.01%	1014

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

QS Investors's CLSD Position: Q2 2021 in Review

QS Investors held its Clearside Biomedical (CLSD) position steady in Q2 2021 at 7,460 shares worth $545K. The position accounts for 0.01% of the portfolio, ranked #703.

QS Investors first reported a position in CLSD in Q1 2021 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold CLSD as of Q2 2021.

QS Investors held 7,460 shares of Clearside Biomedical worth $545K as of Q2 2021.
QS Investors left its Clearside Biomedical share count unchanged in Q2 2021.
Clearside Biomedical made up 0.01% of QS Investors's portfolio in Q2 2021, its #703 holding.
QS Investors first reported a position in Clearside Biomedical in Q1 2021 and has held it in 2 quarters since.
52 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.